• Metoprolol in Translational Research: Optimized Protocols &

  2026-06-19

  Metoprolol, a selective beta1-adrenoceptor antagonist, empowers researchers with precise control over cardiovascular, inflammatory, and tumor biology pathways. Explore advanced experimental workflows, comparative advantages, and troubleshooting strategies that transform APExBIO’s Metoprolol into a cornerstone for translational breakthroughs.

• Capsaicin: Mechanistic Insights and Translational Strategy

  2026-06-19

  Explore the dual mechanistic profile of (E)-Capsaicin as both a TRPV1 ion channel activator and a potent, reversible inhibitor of lysine-specific demethylase 1A (KDM1A/LSD1). This article, anchored by leading studies and APExBIO's rigorously validated capsaicin product, guides translational researchers through state-of-the-art protocols, competitive positioning, and future directions at the intersection of pain, inflammation, and cancer epigenetics research.

• Heptamethine Cyanine Dye Targets PGR in HR+ Breast Cancer

  2026-06-18

  This study introduces CA800-PR, a tumor-targeted heptamethine cyanine dye, which selectively suppresses progesterone receptor (PGR) activity and induces Golgi fragmentation in hormone receptor-positive breast cancer. The findings highlight a multifunctional therapeutic approach that integrates targeted imaging, direct antitumor effects, and immune activation, offering a promising alternative to standard endocrine therapies.

• Bafilomycin C1 in High-Content Phenotypic Screening: Beyond

  2026-06-18

  Explore how Bafilomycin C1, a potent vacuolar H+-ATPases inhibitor, enables next-generation phenotypic screening and mechanistic assays in cellular models. This article provides deep scientific insight, practical protocols, and unique analysis for advanced autophagy and cardiotoxicity research.

• Diethylmaleate (SKU B6151): Precision in Oxidative Stress Re

  2026-06-17

  This article explores laboratory challenges in modeling oxidative stress and resistance, demonstrating how Diethylmaleate (SKU B6151) is a validated, high-purity tool for reproducible glutathione depletion and GST inhibition. Scenario-driven Q&A blocks ground best practices in real data and literature, guiding researchers in redox regulation and toxicology workflows with actionable insights.

• Leupeptin Hemisulfate Salt: Precision Tools for Protease Reg

  2026-06-17

  Explore the scientific intricacies of Leupeptin hemisulfate salt as a reversible, competitive protease inhibitor. This in-depth guide reveals unique mechanistic insights and advanced applications for protein degradation studies, surpassing standard protocols.

• GST-Mediated Resistance in Megalurothrips usitatus to Lambda

  2026-06-16

  This study establishes glutathione S-transferase (GST) as a key mediator of resistance in Megalurothrips usitatus against the pyrethroid insecticide lambda-cyhalothrin. Using diethyl maleate to inhibit GST, the research reveals that GST activity is essential for maintaining antioxidant defenses and pesticide tolerance, offering critical insights for resistance management strategies.

• Mubritinib (TAK 165): Redefining Mitochondrial Targeting in

  2026-06-16

  Explore Mubritinib (TAK 165) as a precise and novel mitochondrial complex I inhibitor, with advanced insights into its selectivity, cytotoxic profile, and unique role in chemoresistant AML and PEL models. This article delivers a deeper look at toxicophore-driven mechanism and practical assay strategy, positioning Mubritinib as an essential tool for translational cancer biology.

• Everolimus (RAD001) in Cell Assays: Validated Experimental S

  2026-06-15

  This article delivers an evidence-based, scenario-driven guide to optimizing cell viability, proliferation, and cytotoxicity assays using Everolimus (RAD001) (SKU A8169). Drawing from primary literature and product-specific data, it addresses practical workflow challenges, interprets quantitative results, and provides actionable protocol insights for biomedical researchers and laboratory personnel.

• SIRT1/2 Inhibitor IV (cambinol): Applied CNS & Tumor Workflo

  2026-06-15

  SIRT1/2 Inhibitor IV (cambinol) enables precision targeting of SIRT1/2 pathways across CNS injury and cancer research. This article delivers actionable protocols, troubleshooting strategies, and expert insights for maximizing data quality and translating metabolic-epigenetic findings into robust experimental outcomes.

• Nebivolol hydrochloride (SKU B1341): Assay Reliability in β1

  2026-06-14

  This scenario-driven guide addresses real-world laboratory challenges facing researchers conducting β1-adrenergic receptor signaling studies, emphasizing the reproducibility and selectivity of Nebivolol hydrochloride (SKU B1341). Using recent peer-reviewed evidence and practical workflow recommendations, we demonstrate how this compound ensures reliable, high-purity β1-adrenoceptor antagonist performance in cell-based assays.

• BMP4-GPX4 Axis Mitigates Ferroptosis in NMDA-Induced Glaucom

  2026-06-13

  This study demonstrates that upregulation of the BMP4-GPX4 signaling axis alleviates ferroptosis and enhances retinal ganglion cell (RGC) differentiation after retinal stem cell transplantation in high intraocular pressure (IOP) glaucoma. By integrating NMDA-induced excitotoxicity models, the work offers mechanistic insight and a robust foundation for translational research in neurodegeneration.

• Ruxolitinib (INCB018424): Protocol Optimization in Myeloprol

  2026-06-12

  Ruxolitinib (INCB018424) from APExBIO delivers highly selective JAK1/2 inhibition, enabling precise dissection of signaling in myeloproliferative disorder research and oncogenic JAK2 fusion protein studies. This article details workflow innovations, troubleshooting strategies, and key experimental parameters to maximize reproducibility and data impact.

• Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO): Pract

  2026-06-12

  The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) prevents unwanted protein degradation during extraction and sample preparation, especially in workflows sensitive to EDTA. It is best suited for applications including Western blotting, co-immunoprecipitation, and kinase assays. It should not be used in workflows requiring metalloprotease inhibition via chelation, as it does not contain EDTA.

• Targeting GOT1 in PDAC: Ziprasidone’s Role in Glutamine Meta

  2026-06-11

  The referenced study identifies ziprasidone as a non-competitive GOT1 inhibitor that disrupts glutamine metabolism in pancreatic ductal adenocarcinoma (PDAC) cells, resulting in impaired proliferation and increased apoptosis. These findings highlight GOT1 as a promising metabolic target for PDAC therapy and demonstrate the utility of molecular probes in mechanistic cancer research.

451 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page